Sickle cell disease: Clinical presentation and management of a global health challenge

M. E. Houwing, P. J. de Pagter, E. J. van Beers, B. J. Biemond, E. Rettenbacher, A. W. Rijneveld, E. M. Schols, J. N. J. Philipsen, R. Y. J. Tamminga, K. Fijn van Draat, E. Nur, M. H. Cnossen, on behalf of the SCORE Consortium

Research output: Contribution to journalReview articleAcademicpeer-review


Sickle cell disease is an autosomal recessive, multisystem disorder, characterised by chronic haemolytic anaemia, painful episodes of vaso-occlusion, progressive organ failure and a reduced life expectancy. Sickle cell disease is the most common monogenetic disease, with millions affected worldwide. In well-resourced countries, comprehensive care programs have increased life expectancy of sickle cell disease patients, with almost all infants surviving into adulthood. Therapeutic options for sickle cell disease patients are however, still scarce. Predictors of sickle cell disease severity and a better understanding of pathophysiology and (epi)genetic modifiers are warranted and could lead to more precise management and treatment. This review provides an extensive summary of the pathophysiology and management of sickle cell disease and encompasses the characteristics, complications and current and future treatment options of the disease.
Original languageEnglish
Article number100580
JournalBlood Reviews
Publication statusPublished - 1 Sep 2019

Cite this